Systematic vitamin D supplementation is associated with improved outcomes and reduced thyroid adverse events in patients with cancer treated with immune checkpoint inhibitors: results from the prospective PROVIDENCE study.

Plain-language guide to PMID 37638980 (2023): observational study of Vitamin D, K2, Magnesium and Zinc, immune system (general).

Key Facts

PMID: 37638980
Journal: Cancer immunology, immunotherapy : CII
Year: 2023
Study type: Observational Study
Authors: Bersanelli M et al. (28 authors)
DOI: 10.1007/s00262-023-03522-3

What This Study Did, in Plain Language

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in the context of immune system (general) in this observational study publication.

The researchers planned a prospective observational study (PROVIDENCE) to assess serum vitamin D levels in patients with advanced cancer receiving ICIs (cohort 1 at treatment initiation, cohort 2 during treatment) and the impact of systematic repletion on survival and toxicity outcomes.

Why It Was Studied

Hypovitaminosis D can have a negative prognostic impact in patients with cancer.

The researchers hypothesized that systematic vitamin D repletion could impact clinical outcomes in patients with cancer receiving immune-checkpoint inhibitors (ICIs).

Who Took Part

In an exploratory analysis, the researchers compared the clinical outcomes of cohort 1 with a control cohort of patients followed at the participating centers who did not receive systematic vitamin D repletion.

What Was Measured

The researchers hypothesized that systematic vitamin D repletion could impact clinical outcomes in patients with cancer receiving immune-checkpoint inhibitors (ICIs).

PubMed files the paper under topics including Immune Checkpoint Inhibitors, Vitamin D, Thyroid Gland, Antineoplastic Agents, Immunological, Neoplasms and Dietary Supplements.

Author keywords: Cancer, Cholecalciferol, Immune related adverse events and Immunotherapy.

What This Means in Plain Language

This is an observational study of Vitamin D, K2, Magnesium and Zinc in people with immune system (general).

Its findings take up roughly 9 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2023 (Cancer immunology, immunotherapy : CII), a journal based in Germany.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, Immune system (general) research.

Our Notes on the Compound

Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.